Skip to main content
Fig. 3 | Infectious Agents and Cancer

Fig. 3

From: Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Fig. 3

A Neutrophil/lymphocyte ratio, B leukocyte/lymphocyte ratio, C platelet/lymphocyte ratio, D monocyte/lymphocyte ratio, E C-reactive protein (CRP), F CRP/albumin ratio, G procalcitonin, and H interleukin-6 in the azithromycin and placebo groups at visit 1, 2, and end of study (EoS). p-values as determined by likelihood ratio test (LRT) for the interaction term between treatment group and visit

Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us